A detailed history of Huntington National Bank transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Huntington National Bank holds 94 shares of ALNY stock, worth $22,611. This represents 0.0% of its overall portfolio holdings.

Number of Shares
94
Previous 49 91.84%
Holding current value
$22,611
Previous $11,000 127.27%
% of portfolio
0.0%
Previous 0.0%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 06, 2024

BUY
$233.81 - $287.01 $10,521 - $12,915
45 Added 91.84%
94 $25,000
Q2 2024

Aug 08, 2024

SELL
$143.31 - $247.0 $2,579 - $4,446
-18 Reduced 26.87%
49 $11,000
Q1 2024

May 03, 2024

BUY
$146.51 - $198.2 $5,127 - $6,937
35 Added 109.38%
67 $10,000
Q4 2023

Feb 07, 2024

BUY
$151.41 - $196.57 $302 - $393
2 Added 6.67%
32 $6,000
Q3 2023

Nov 08, 2023

SELL
$170.77 - $211.65 $2,049 - $2,539
-12 Reduced 28.57%
30 $5,000
Q2 2023

Aug 11, 2023

BUY
$185.01 - $212.05 $4,255 - $4,877
23 Added 121.05%
42 $7,000
Q1 2023

May 10, 2023

BUY
$182.66 - $235.53 $3,287 - $4,239
18 Added 1800.0%
19 $3,000
Q4 2022

Feb 09, 2023

BUY
$185.53 - $241.31 $185 - $241
1 New
1 $0
Q1 2022

May 10, 2022

SELL
$127.18 - $173.91 $10,301 - $14,086
-81 Closed
0 $0
Q4 2021

Jan 21, 2022

SELL
$159.56 - $209.29 $797 - $1,046
-5 Reduced 5.81%
81 $14,000
Q3 2021

Oct 28, 2021

BUY
$169.75 - $207.73 $848 - $1,038
5 Added 6.17%
86 $16,000
Q1 2021

Apr 12, 2021

BUY
$126.83 - $175.69 $10,273 - $14,230
81 New
81 $11,000
Q2 2020

Jul 30, 2020

SELL
$104.21 - $156.44 $30,846 - $46,306
-296 Closed
0 $0
Q4 2019

Jan 17, 2020

BUY
$74.51 - $124.23 $22,054 - $36,772
296 New
296 $34,000
Q1 2019

Apr 09, 2019

SELL
$72.76 - $93.45 $72,760 - $93,450
-1,000 Closed
0 $0
Q4 2018

Jan 28, 2019

BUY
$62.67 - $88.33 $62,670 - $88,330
1,000 New
1,000 $73,000

Others Institutions Holding ALNY

About ALNYLAM PHARMACEUTICALS, INC.


  • Ticker ALNY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 123,028,000
  • Market Cap $29.6B
  • Description
  • Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...
More about ALNY
Track This Portfolio

Track Huntington National Bank Portfolio

Follow Huntington National Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Huntington National Bank, based on Form 13F filings with the SEC.

News

Stay updated on Huntington National Bank with notifications on news.